OKYO_Pharma appoints Marta_Sacchetti to SAB

OKYO Pharma>>>, a clinical-stage biopharmaceutical company, announced the expansion of its Scientific Advisory Board with the appointment of Marta Sacchetti>>>, MD, PhD. Marta Sacchetti>>> is an Associate Professor of Ophthalmology at Link University>>> in Rome, Italy, and previously served as Global Head of Clinical Development, Ophthalmology & Neurotrophins at Dompé Farmaceutici>>>. Her expertise in neuro-inflammatory corneal diseases is expected to strengthen OKYO Pharma>>>'s global scientific network and help shape the clinical development strategy for its lead drug candidate, Urgoskin>>>. Urgoskin>>> is an investigational therapy for neuropathic corneal pain (NCP) and has received Fast Track designation from the United States — Food and Drug Administration>>>. OKYO Pharma>>> recently completed a Phase 2 trial for Urgoskin>>> in NCP patients and plans to initiate a Phase 2b/3 multiple-dose study. The company's CEO, Robert Dempsey>>>, and CMO, Flavio Mantelli>>>, highlighted the importance of Marta Sacchetti>>>'s addition to the board.